Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
IMWG consensus on maintenance therapy in multiple myeloma
Heinz Ludwig
, Brian G.M. Durie
, Philip McCarthy
, Antonio Palumbo
, Jésus San Miguel
, Bart Barlogie
, Gareth Morgan
, Pieter Sonneveld
, Andrew Spencer
, Kenneth C. Andersen
, Thierry Facon
, Keith A. Stewart
, Hermann Einsele
, Maria Victoria Mateos
, Pierre Wijermans
, Anders Waage
, Meral Beksac
, Paul G. Richardson
, Cyrille Hulin
, Ruben Niesvizky
Henk Lokhorst, Ola Landgren, P. Leif Bergsagel, Robert Orlowski, Axel Hinke, Michele Cavo, Michel Attal
Show 7 others
Show less
Research output
:
Contribution to journal
›
Review article
›
peer-review
185
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'IMWG consensus on maintenance therapy in multiple myeloma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Multiple Myeloma
100%
Maintenance Therapy
100%
Thalidomide
100%
Overall Survival
80%
Progression-free Survival
80%
Bortezomib
60%
Prednisone
60%
Maintenance Treatment
60%
Significant Risk Factors
40%
Risk Reduction
40%
Induction Therapy
40%
Melphalan
40%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
40%
In(III)
20%
Meta-analysis
20%
Elderly Patients
20%
Treatment Decisions
20%
Response Quality
20%
Successful Induction
20%
Potential Gains
20%
Potential Risk
20%
Lenalidomide
20%
International Myeloma Working Group
20%
Group Review
20%
Lenalidomide Maintenance
20%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Thalidomide
100%
Overall Survival
80%
Progression Free Survival
80%
Bortezomib
60%
Prednisone
60%
Lenalidomide
40%
Melphalan
40%
Myeloma
20%
Side Effect
20%
Medicine and Dentistry
Multiple Myeloma
100%
Maintenance Therapy
100%
Thalidomide
62%
Progression Free Survival
50%
Overall Survival
50%
Prednisone
37%
Bortezomib
37%
Risk Reduction
25%
Melphalan
25%
Lenalidomide
25%
Autologous Stem Cell Transplantation
25%
Myeloma
12%
Elderly Patient
12%
Meta-Analysis
12%
Side Effect
12%
Nursing and Health Professions
Maintenance Therapy
100%
Multiple Myeloma
100%
Thalidomide
62%
Overall Survival
50%
Progression Free Survival
50%
Prednisone
37%
Velcade
37%
Melphalan
25%
Autologous Stem Cell Transplantation
25%
Lenalidomide
25%
Meta Analysis
12%
Elderly Patient
12%
Myeloma
12%
Side Effect
12%
Immunology and Microbiology
Multiple Myeloma
100%
Thalidomide
100%
Overall Survival
80%
Progression Free Survival
80%
Prednisone
60%
Lenalidomide
40%
Autologous Stem Cell Transplantation
40%